Effect of L-Carnitine Supplementation associated with muscle sympton, renal anemia and cardiac function in dialysis patients.
Not Applicable
- Conditions
- Chronic kidney disease (dialysis patients)
- Registration Number
- JPRN-UMIN000007874
- Lead Sponsor
- Juntendo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
allergy of L-Carnitine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvements of muscle sympton, renal anemia and cardiac function.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link L-Carnitine to improved mitochondrial function in dialysis-related muscle symptoms?
How does L-Carnitine supplementation compare to erythropoiesis-stimulating agents in managing renal anemia in hemodialysis patients?
Which biomarkers correlate with L-Carnitine efficacy in dialysis patients with cardiac dysfunction and muscle weakness?
What are the safety profiles of L-Carnitine in chronic hemodialysis populations, particularly regarding arrhythmia risk?
How do L-Carnitine combinations with iron or vitamin D impact anemia and cardiac outcomes in ESRD patients compared to monotherapy?